南通大学学报（医学版）
南通大學學報（醫學版）
남통대학학보（의학판）
JOURNAL OF NANTONG UNIVERSITY(MEDICAL SCIENCES)
2015年
2期
126-128,129
,共4页
乳腺癌%甲状腺激素%CA153%高敏C-反应蛋白%早期诊断
乳腺癌%甲狀腺激素%CA153%高敏C-反應蛋白%早期診斷
유선암%갑상선격소%CA153%고민C-반응단백%조기진단
breast cancer%thyroid hormone%CA153%high-sensitive C-reactive protein%early diagnosis
目的：探讨乳腺癌患者治疗前后测定甲状腺激素(thyroid hormone, TH)，CA153和高敏C-反应蛋白(high-sensitive C-reactive protein, hs-CRP)水平的临床价值。方法：采用化学发光免疫分析和免疫比浊定量法测定了156例乳腺癌患者治疗前后和60例正常对照组血清TH，包括3,3’,5-三碘-L-甲腺原氨酸[O-(4-Hydroxy-3-iodophenyl)-3,5-di-iodo-L-tyrosine, T3]、游离型T3(free T3， FT3)、L-甲状腺素(L-thyroxine, T4)、游离型 T4(free T4， FT4)和促甲状腺激素(thyroid stimulating hormone, TSH), CA153和hs-CRP水平，进行了对比性分析。结果：在治疗前，乳腺癌患者血清T3和FT3水平较正常对照组明显降低(均P<0.01)，并随乳腺癌Ⅰ~Ⅳ期严重程度的增加而降低；血清FT4水平降低(P<0.05)。血清T4和TSH水平差异无统计学意义(均P＞0.05)；血清CA153和hs-CRP水平较正常对照组明显增高(均P<0.01)，且随乳腺癌严重程度的增加而增高。乳腺癌患者治疗后，Ⅰ、Ⅱ期患者血清T3和FT3水平恢复至正常水平，CA153和hs-CRP为正常水平(均P＞0.05)；Ⅲ、Ⅳ期患者血清T3和FT3水平明显增高，CA153和hs-CRP水平明显降低(P<0.05, P<0.01)。结论：血清T3和FT3水平降低以及血清CA153和hs-CRP水平明显增高是乳腺癌早期诊断的良好指标，并具有治疗后随访的临床价值。
目的：探討乳腺癌患者治療前後測定甲狀腺激素(thyroid hormone, TH)，CA153和高敏C-反應蛋白(high-sensitive C-reactive protein, hs-CRP)水平的臨床價值。方法：採用化學髮光免疫分析和免疫比濁定量法測定瞭156例乳腺癌患者治療前後和60例正常對照組血清TH，包括3,3’,5-三碘-L-甲腺原氨痠[O-(4-Hydroxy-3-iodophenyl)-3,5-di-iodo-L-tyrosine, T3]、遊離型T3(free T3， FT3)、L-甲狀腺素(L-thyroxine, T4)、遊離型 T4(free T4， FT4)和促甲狀腺激素(thyroid stimulating hormone, TSH), CA153和hs-CRP水平，進行瞭對比性分析。結果：在治療前，乳腺癌患者血清T3和FT3水平較正常對照組明顯降低(均P<0.01)，併隨乳腺癌Ⅰ~Ⅳ期嚴重程度的增加而降低；血清FT4水平降低(P<0.05)。血清T4和TSH水平差異無統計學意義(均P＞0.05)；血清CA153和hs-CRP水平較正常對照組明顯增高(均P<0.01)，且隨乳腺癌嚴重程度的增加而增高。乳腺癌患者治療後，Ⅰ、Ⅱ期患者血清T3和FT3水平恢複至正常水平，CA153和hs-CRP為正常水平(均P＞0.05)；Ⅲ、Ⅳ期患者血清T3和FT3水平明顯增高，CA153和hs-CRP水平明顯降低(P<0.05, P<0.01)。結論：血清T3和FT3水平降低以及血清CA153和hs-CRP水平明顯增高是乳腺癌早期診斷的良好指標，併具有治療後隨訪的臨床價值。
목적：탐토유선암환자치료전후측정갑상선격소(thyroid hormone, TH)，CA153화고민C-반응단백(high-sensitive C-reactive protein, hs-CRP)수평적림상개치。방법：채용화학발광면역분석화면역비탁정량법측정료156례유선암환자치료전후화60례정상대조조혈청TH，포괄3,3’,5-삼전-L-갑선원안산[O-(4-Hydroxy-3-iodophenyl)-3,5-di-iodo-L-tyrosine, T3]、유리형T3(free T3， FT3)、L-갑상선소(L-thyroxine, T4)、유리형 T4(free T4， FT4)화촉갑상선격소(thyroid stimulating hormone, TSH), CA153화hs-CRP수평，진행료대비성분석。결과：재치료전，유선암환자혈청T3화FT3수평교정상대조조명현강저(균P<0.01)，병수유선암Ⅰ~Ⅳ기엄중정도적증가이강저；혈청FT4수평강저(P<0.05)。혈청T4화TSH수평차이무통계학의의(균P＞0.05)；혈청CA153화hs-CRP수평교정상대조조명현증고(균P<0.01)，차수유선암엄중정도적증가이증고。유선암환자치료후，Ⅰ、Ⅱ기환자혈청T3화FT3수평회복지정상수평，CA153화hs-CRP위정상수평(균P＞0.05)；Ⅲ、Ⅳ기환자혈청T3화FT3수평명현증고，CA153화hs-CRP수평명현강저(P<0.05, P<0.01)。결론：혈청T3화FT3수평강저이급혈청CA153화hs-CRP수평명현증고시유선암조기진단적량호지표，병구유치료후수방적림상개치。
Objective: To explor e the clinical value of determining serum thyroid hormone ( TH ) , CA153 and high-sensitive C-reactive protein(hs-CRP) in patients with breast cancer. Methods:The serum TH, CA153 and hs-CRP levels were determined in 156 patients with breast cancer and 60 normal controls by chemiluminescence immunoassay and immunofluorescent dry quantitative method, and which was compared. Results: Before therapy, the serum T3 and FT3 levels in 156 patients with breast cancer were significantly lower than those in 60 controls (all P<0.01), and decreased with severity (Ⅰ-Ⅳ stage of breast cancer), the serum FT4 level decreased (all P<0.05). The serum CA153 and hs-CRP levels in 156 patients with breast cancer were significantly higher than those in 60 controls(all P<0.01), and increased with severity(Ⅰ-Ⅳstage of breast cancer). In 156 patients with breast cancer after therapy, the serum T3 and FT3 levels in Ⅰstage and Ⅱstage patients with breast cancer were returned to normal levels (all P>0.05), the serum T3 and FT3 levels inⅢstage andⅣstage patients with breast cancer were significantly increased(P<0.05, P<0.01). The serum CA153 and hs-CRP levels inⅠstage andⅡstage patients with breast cancer were returned to normal levels(all P>0.05), the serum CA153 and hs-CRP levels inⅢstage andⅣstage patients with breast cancer were significantly decreased(P<0.05, P<0.01). Conclusion:That the serum T3 and FT3 levels decreased as well as serum CA153 and hs-CRP levels significantly increased were a good index for early diagnostic breast cancer, which has clinical value for follow-up after therapy.
